GoodRx Secures Eli Lilly GLP-1 Partnership, Aligning with Pharma Solutions Growth Strategy

What happened

GoodRx announced a partnership with Eli Lilly to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo, offering it at a starting price of $149 per month for self-pay patients across over 70,000 pharmacies nationwide. This move directly supports GoodRx's strategic pivot towards its rapidly growing pharma manufacturer solutions segment, which surged 54% year-over-year in Q3 2025 as noted in the DeepValue report. The collaboration leverages GoodRx's extensive pharmacy network and data scale to tap into the high-demand GLP-1 market, aiming to drive incremental revenue through transparent pricing. However, the core prescription transactions business continues to face structural headwinds, with MAUs declining to 5.4 million and revenue down 9% YoY in Q3 2025 due to PBM program changes and pharmacy closures. While this partnership is a positive step in diversifying revenue streams, it must be critically assessed against ongoing regulatory risks and the need for pharma solutions to fully offset persistent declines in the legacy coupon segment.

Implication

First, the Eli Lilly collaboration validates GoodRx's ability to attract major drugmakers, potentially accelerating revenue growth in the pharma manufacturer solutions segment, which carries higher margins. Second, it could enhance GoodRx's market positioning in the lucrative GLP-1 category, attracting similar partnerships and supporting the transition narrative away from reliance on prescription transactions. Third, success here may improve investor confidence in the company's strategic shift, as highlighted in the DeepValue report's watch items on mix shift. Fourth, however, the financial impact remains uncertain and likely modest relative to the $35–$40 million headwind from core segment pressures, requiring continued monitoring of volume trends. Fifth, investors must remain cautious, as regulatory scrutiny and PBM competition could undermine long-term economics, making sustained execution in pharma solutions critical to justifying the current undervaluation.

Thesis delta

This news slightly strengthens the investment thesis by providing concrete evidence of GoodRx's ability to scale its pharma manufacturer solutions, a key growth offset to core prescription transaction declines. However, it does not materially shift the cautious stance, as the partnership's contribution is unquantified and core business challenges persist, with MAU drops and regulatory risks remaining high. Thus, the thesis remains a potential buy contingent on further validation of pharma solutions growth and stabilization in the legacy segment.